Supreme Court Allows Mail-Order of Abortion Pill Mifepristone Pending Appeal
The U.S. Supreme Court has ruled to allow the mail-order distribution of the abortion medication mifepristone while an appeal challenging this method proceeds. This decision effectively maintains a temporary stay on a nationwide ban issued by the 5th Circuit U.S. Court of Appeals on May 1, which had prohibited mailing the drug. The legal battle originated when Louisiana, a state with strict abortion bans, sued the Food and Drug Administration (FDA) over its 2023 decision to remove the in-person dispensing requirement for mifepristone. Although the Supreme Court did not disclose the vote count or provide a majority explanation, conservative Justices Clarence Thomas and Samuel Alito issued written dissents against extending the stay. Pharmaceutical manufacturers Danco Laboratories and GenBioPro had petitioned the high court to lift the lower court's ban. This ruling marks a significant development in the ongoing legal conflicts surrounding reproductive rights and FDA regulatory authority following the overturning of federal constitutional protections for abortion. The decision ensures continued access to mail-order mifepristone across the United States until the appellate process concludes.
Editorial responsibility
- No named human review is recorded for this page.
- Reports are grouped by semantic similarity and deterministic rules. Language models may assist titles, summaries, translation and cross-source analysis; the page itself is projected from evidence records.
- Current automated evidence projection